Funding for this research was provided by:
National Institutes of Health (K25HL121295, U01HG009080, R01HG006399, R01CA227237, R01ES029929, R01HG011345, R01CA227237, R01CA244569)
U.S. Department of Defense (W81XWH-16-2-0018)
Doris Duke Charitable Foundation
Louis B. Mayer Foundation
Received: 8 April 2021
Accepted: 28 October 2021
First Online: 8 November 2021
: PROFILE samples were selected and sequenced from patients who were consented under institutional review board (IRB)-approved protocol 11-104 and 17-000 from the Dana-Farber/Partners Cancer Care Office for the Protection of Research Subjects. Written informed consent was obtained from participants prior to inclusion in this study. Secondary analyses of previously collected data were performed with approval from the Dana-Farber IRB (DFCI IRB protocol 19-033 and 19-025; waiver of HIPAA authorization approved for both protocols). The research conformed to the principles of the Helsinki Declaration.
: Not applicable.
: The authors declare that they have no competing interests.